ECSP21087299A - Composiciones y métodos para tratar el virus de la hepatitis c - Google Patents

Composiciones y métodos para tratar el virus de la hepatitis c

Info

Publication number
ECSP21087299A
ECSP21087299A ECSENADI202187299A ECDI202187299A ECSP21087299A EC SP21087299 A ECSP21087299 A EC SP21087299A EC SENADI202187299 A ECSENADI202187299 A EC SENADI202187299A EC DI202187299 A ECDI202187299 A EC DI202187299A EC SP21087299 A ECSP21087299 A EC SP21087299A
Authority
EC
Ecuador
Prior art keywords
virus
subject
methods
effective amount
amount
Prior art date
Application number
ECSENADI202187299A
Other languages
English (en)
Inventor
Vahid Zia
Charles Reynolds
Darryl Cleary
Dimitrios Stefanidis
Reza Oliyai
Melissa Casteel
Robert Hindes
Miriam Berrey
Rowchanak Pakdaman
Hongmei Mo
William Symonds
Adrian Ray
Christy Hebner
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of ECSP21087299A publication Critical patent/ECSP21087299A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se divulga una composición y forma de dosificación unitaria para el tratamiento de una infección causada por el virus de la hepatitis C (VHC) que comprende GS-7977 y al menos un excipiente farmacéuticamente aceptable, así como también los métodos para la fabricación de dicha composición y forma de dosificación unitaria. También en el presente documento se divulga un método para tratar a un sujeto, preferentemente un ser humano, infectado con el virus de la hepatitis C, dicho método comprende administrar al sujeto durante un período de tiempo una cantidad efectiva de GS-7977 y una cantidad efectiva de ribavirina. En un aspecto, el método comprende administrar al sujeto un régimen de tratamiento libre de interferón que comprende una cantidad efectiva de GS-7977 y una cantidad efectiva de ribavirina. En un aspecto particular, el método es suficiente para producir en el sujeto una cantidad indetectable de ARN del VHC durante al menos 12 semanas después de finalizado el período de tiempo.
ECSENADI202187299A 2011-11-29 2021-12-02 Composiciones y métodos para tratar el virus de la hepatitis c ECSP21087299A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
ECSP21087299A true ECSP21087299A (es) 2022-02-25

Family

ID=48803225

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202187299A ECSP21087299A (es) 2011-11-29 2021-12-02 Composiciones y métodos para tratar el virus de la hepatitis c

Country Status (4)

Country Link
AP (1) AP2014007699A0 (es)
EC (1) ECSP21087299A (es)
IL (1) IL232889A (es)
MY (1) MY187735A (es)

Also Published As

Publication number Publication date
MY187735A (en) 2021-10-15
IL232889A0 (en) 2014-07-31
AP2014007699A0 (en) 2014-06-30
IL232889A (en) 2016-07-31

Similar Documents

Publication Publication Date Title
ECSP14005678A (es) Composiciones y métodos para tratar el virus de la hepatitis c
AR088580A1 (es) Metodos y composiciones para tratar el virus de la hepatitis c
ECSP12012067A (es) Inhibidores del virus de la hepatitis c
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
CO6592102A2 (es) Compuestos de sililo triciclicos fusionados y metodos de uso de los mismos para el tratamiento de enfermedades virales
UY37997A (es) Agentes antivirales contra la hepatitis b
ECSP14013315A (es) Inhibidores de aplicación viral
MX2018013782A (es) Antigenos y vacunas dirigidos contra enterovirus humanos.
EA201290575A1 (ru) Ингибиторы вирусов flaviviridae
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
EA201290576A1 (ru) Ингибиторы вирусов flaviviridae
AR084237A1 (es) Metodos para tratar virus de hepatitis c (hcv), composicion
ECSP12011845A (es) Nuevos inhibidores macrocíclicos de la replicación
UY33897A (es) Inhibidores del virus de la hepatitis c
EA201200890A1 (ru) Комбинированная терапия hcv
CO6430434A2 (es) Nuevas composiciones de vacunas con pertussis acelular y método de fabricación de las mismas
GT201500046A (es) Mètodos para el tratamiento de infecciones de hepatitis b y hepatitis d
UY34066A (es) Inhibidores del virus de la hepatitis c
MX2013000242A (es) Tratamiento de enfermedades relacionadas con el virus de hepatitis c que usa hidroxicloroquina o una combinacion de hidroxicloroquina y un agente antiviral.
CO6640318A2 (es) Formas de dosificación oral de bendamustina
ECSP21087299A (es) Composiciones y métodos para tratar el virus de la hepatitis c
UA114097C2 (xx) Композиція (варіанти) та спосіб (варіанти) лікування вірусного гепатиту с
CR20140273A (es) Composiciones y métodos para tratar el virus de la hepatitis c
CL2014001397A1 (es) Composicion farmaceutica que comprende a) gs-7977 y b) al menos un excipiente farmaceuticamente estable; forma de dosificacion unitaria; proceso de preparacion de la composicion; uso de la composicion para tratar una infeccion causada por el virus de la hepatitis c.
NI201400025A (es) Inhibidores de aplicación viral